Dunja Aksentijevic Ricciarelli
Dunja Aksentijevic Ricciarelli @dunjaaks ·
Grateful for the opportunity to contribute to the new scientific statement from the @escardio on metabolic dysfunction and cardiovascular disease. A great collaborative effort across ESC Basic Science Council and Working Groups. #CardioScience #ESC academic.oup.com/eurheartj/adva…
featured image
Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities: A scientific...

Abstract. Metabolic disorders such as obesity, type 2 diabetes, and dyslipidaemia are major drivers of cardiovascular risk and have reached epidemic levels

From academic.oup.com
2
629
Vivian Taylor
Vivian Taylor @unfunnymom453 ·
New research reveals Semaglutide may offer organ-protective benefits in HFpEF, highlighting its potential beyond glycemic control and weight management. 🚀 Read more here:pharmacyuk.com/semaglutide-de…V �� #CardioScience #HFpEF #Semaglutide
Semaglutide Demonstrates Organ-Protective Effects in HFpEF, New Research Shows - Pharmacy UK

Semaglutide , best known as a treatment for obesity and type 2 diabetes, may offer direct organ protection in people with a common form of heart failure, new research suggests. The findings have...

From pharmacyuk.com
23
KhalilYounis_Official
KhalilYounis_Official @khalilraja126 ·
Excited to follow the latest ESC insights! The TOMAHAWK substudy highlights a key message: immediate angiography after OHCA without ST-elevation shows no survival benefit — even in patients >75. Important evidence shaping future care. @escardio #CardioScience #ESC2025
16